Profusa, Inc. Common Stock (PFSA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Profusa, Inc. Common Stock (PFSA) has a cash flow conversion efficiency ratio of 0.091x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.58 Million) by net assets ($-28.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see PFSA market cap overview for the company's overall valuation and market capitalisation.
Profusa, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Profusa, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Profusa, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Profusa, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore PFSA cash flow quality score to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anpario Plc
LSE:ANP
|
0.112x |
|
Ristia Bintang Mahkotasejati
JK:RBMS
|
0.003x |
|
Shree Ram Proteins Limited
NSE:SRPL
|
0.071x |
|
Marwyn Value Investors Limited
LSE:MVI
|
0.017x |
|
IG Design Group plc
LSE:IGR
|
0.380x |
|
N.W.F Group
LSE:NWF
|
0.215x |
|
Marshall Machines Limited
NSE:MARSHALL
|
-0.164x |
|
Science in Sport plc
LSE:SIS
|
0.025x |
Annual Cash Flow Conversion Efficiency for Profusa, Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Profusa, Inc. Common Stock from 2021 to 2025. View current stock price of Profusa, Inc. Common Stock for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-26.66 Million | $-16.25 Million | 0.609x | +3416.71% |
| 2024-12-31 | $-119.20 Million | $-2.07 Million | 0.017x | -56.69% |
| 2023-12-31 | $-110.00 Million | $-4.40 Million | 0.040x | -48.16% |
| 2022-12-31 | $-99.77 Million | $-7.70 Million | 0.077x | -39.59% |
| 2021-12-31 | $-83.66 Million | $-10.69 Million | 0.128x | -- |
About Profusa, Inc. Common Stock
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platf… Read more